Amgen and AstraZeneca Drug Combination Shows Significant Survival Benefit in Advanced Small Cell Lung Cancer

A combination therapy involving Amgen's Imdelltra and AstraZeneca's Imfinzi has demonstrated an eight-month extension in survival compared to Imfinzi alone for patients with advanced small cell lung cancer. The trial, whose findings were presented at the European Society for Medical Oncology (ESMO) Congress and published in the New England Journal of Medicine, reported a 58% reduction in the risk of death.